bretylium

01/01/1987 - "This study was performed to assess the role of cardiac sympathetic nerves in the in vivo antifibrillatory action of bretylium using the technique of electrically induced ventricular fibrillation. "
06/01/1993 - "Since the use of bretylium was instituted, there have been no cases of ventricular fibrillation in a series of 20 animals. "
07/01/1986 - "The conclusions of the present review strongly support those of the United States Food and Drug Administration, approving bretylium for prophylaxis and treatment of ventricular fibrillation."
07/01/1986 - "Deleterious effects of bretylium on hemodynamic recovery from ventricular fibrillation."
03/01/1986 - "Thus, it can be concluded that interaction with adrenergic neurons is important for bretylium's antifibrillatory action and that absence of sympathetic neurotransmission contributes to the elevation of ventricular fibrillation threshold."

08/01/1988 - "Clinical suppression of refractory ventricular tachycardia with oral bretylium not predicted by electrophysiologic drug testing."
05/01/1985 - "Bretylium is a class III antiarrhythmic agent which is used for the management of serious and refractory ventricular tachyarrhythmias. "
02/01/1985 - "Pharmacologic responses to a placebo infusion and 3 separate bretylium infusions (2.5, 5.0, 10 mg/kg over 60 minutes) were assessed in 6 patients with recurrent, nonsustained ventricular tachycardia. "
06/01/1983 - "In one patient, ventricular tachycardia could not be induced after intravenous bretylium."
06/01/1983 - "Thirty minutes after this infusion, sustained ventricular tachycardia could be induced in 9 of the 10 patients (one of these nine patients also had bretylium-potentiated spontaneous ventricular tachycardia). "

10/15/2020 - "This article provides a history of the salient trials evaluating the efficacy and safety of bretylium and looks to the future as bretylium finds its place in the modern day management of ventricular arrhythmia."
07/01/1992 - "During cooling, the ventricular arrhythmia threshold (VAT) in control animals decreased from 10.1 +/- 1.9 to 4.4 +/- 1.3 impulses, while the VAT in bretylium-treated animals increased from 9.8 +/- 2.9 to 23.2 +/- 2.7 impulses. "
03/01/1989 - "In four dogs, bretylium (10 mg/kg) did not alter the time course of electrogram changes nor the time to onset of arrhythmia. "
01/01/1985 - "Bretylium is thus likely to continue to find increasing usage in the acute management of malignant ventricular arrhythmia."
09/01/1975 - "Bretylium pretreatment shortened the duration of the ventricular arrhythmia. "

01/01/2019 - "Little clinical data exist on efficacy of anti-arrhythmic drugs in hypothermia, while experimental data show the potential of some agents, such as the class III antiarrhythmic bretylium. "
11/01/1984 - "Despite the possible value of prophylactic bretylium in the setting of hypothermia, its use as active treatment for hypothermia-induced ventricular fibrillation in dogs does not seem to be beneficial."
03/01/2003 - "Bretylium was removed from Advanced Cardiac Life Support guidelines, and, to date, efficacy of amiodarone in hypothermia is unknown. "

01/01/1988 - "The bretylium-treated animals also exhibited an improved renal pathology index but they did not differ from the controls with respect to proteinuria and hematuria. "
12/01/1988 - "In MRL/1 bretylium and both ACE inhibitors improved renal histopathology, but only captopril prolonged survival, and it decreased proteinuria and haematuria. "